ClinicalTrials.gg

Program

venetoclax

Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.

Furthest: phase 4, since Nov 22, 202167 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie5312 open or runningphase 4since Nov 22, 2021Apr 1, 2011Nov 2026phase 2 · NCT04895436
Hoffmann-La Roche131 open or runningphase 3since Dec 4, 2013Aug 10, 2012none ahead
Oncotherapeutics11 open or runningphase 2since Aug 11, 2023Aug 11, 2023none ahead

Also a collaborator on its studies: Johnson & Johnson, baili-bio-chengdu-pharmaceutical-co-ltd, roche-genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Oct 12, 2012.

  1. Jun 5, 2020Phase 1 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04422210 · 2 enrolled · United States, Denmark, Korea, Republic of and more
  2. Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellAbbVie · NCT04477486 · 13 enrolled · Japan
  3. Aug 10, 2020Phase 3 study in Leukemia, Myeloid, AcuteAbbVie · NCT04509622 · 14 enrolled · Japan
  4. Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04790903 · 50 enrolled · United States, France, Italy and more
  5. Mar 19, 2021Phase 1 study in Renal InsufficiencyAbbVie · NCT04810598 · 12 enrolled · United States
  6. May 19, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436 · 75 planned · United States, Australia, Austria and more
  7. Nov 22, 2021Phase 4 study in Leukemia, Myeloid, AcuteAbbVie · NCT05144243 · 44 enrolled · China
  8. Jun 12, 2023Phase 1 study in Healthy VolunteersAbbVie · NCT05909553 · 15 enrolled · United States
  9. Aug 11, 2023Oncotherapeutics's first study: phase 2 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT06115135 · 39 planned · United States
  10. Oct 2, 2023Phase 1 study in Healthy VolunteersAbbVie · NCT06070948 · United States
  11. Jul 23, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT06524375 · 118 enrolled · United States
  12. Dec 17, 2024Phase 1 study in Healthy VolunteerAbbVie · NCT06742086 · 72 enrolled · United States
  13. Jun 23, 2025Phase 4 study in Leukemia, Myeloid, AcuteAbbVie · NCT07044687 · 100 planned · India
  14. Jan 28, 2026Phase 2 study in Waldenstrom MacroglobulinemiaAbbVie · NCT07387471 · 14 enrolled · Japan

Ahead

  1. Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436
  2. Jun 2027Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT02899052
  3. Jul 2027Primary completion: phase 3 study in Myelodysplastic SyndromesAbbVie · NCT04401748
  4. Aug 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT03844048

TargetBeta

BCL2 →read by rule
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

The newest 60 of 67 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07387471Waldenstrom Macroglobulinemia · Japan2Active, not recruitingAbbVieJul 202814
NCT07044687Leukemia, Myeloid, Acute · India4RecruitingAbbVieNov 2027100
NCT06742086Healthy Volunteer · United States1CompletedAbbVieOct 8, 202572
NCT06524375Leukemia, Lymphocytic, Chronic, B-Cell · United States2Active, not recruitingHoffmann-La RocheOct 28, 2026118
NCT06070948Healthy Volunteers · United States1WithdrawnAbbVieJul 28, 20250
NCT06115135Multiple Myeloma · United States2RecruitingOncotherapeuticsApr 30, 202639
NCT05909553Healthy Volunteers · United States1CompletedAbbVieSep 22, 202315
NCT05144243Leukemia, Myeloid, Acute · China4Active, not recruitingAbbVieMar 202644
NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2RecruitingAbbVieNov 202675
NCT04810598Renal Insufficiency · United States1CompletedAbbVieAug 16, 202212
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedHoffmann-La RocheMay 21, 202450
NCT04509622Leukemia, Myeloid, Acute · Japan3CompletedAbbVieApr 15, 202114
NCT04477486Lymphoma, Mantle-Cell · Japan2CompletedAbbVieFeb 9, 202213
NCT04422210Small Cell Lung Carcinoma · United States, Denmark, Korea, Republic of and more1TerminatedHoffmann-La RocheNov 6, 20202
NCT04401748Myelodysplastic Syndromes · United States, Australia, Austria and more3Active, not recruitingAbbVieJul 2027531
NCT04298918Breast Neoplasms · Australia, Korea, Republic of2TerminatedHoffmann-La RocheFeb 4, 20211
NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3CompletedHoffmann-La RocheMar 19, 2024166
NCT04274933Breast Neoplasms · United States, Germany, Japan and more1TerminatedAbbVieOct 8, 20204
NCT04274907Carcinoma, Non-Small-Cell Lung · United States1TerminatedAbbVieFeb 2, 20212
NCT04161885Leukemia, Myeloid, Acute · United States, Australia, Brazil and more3TerminatedAbbVieSep 23, 2025465
NCT04102020Leukemia, Myeloid, Acute · United States, Australia, Canada and more3CompletedAbbVieSep 29, 2022112
NCT03873493Leukemia · United States, Australia, Austria and more2CompletedAbbVieNov 4, 202114
NCT03844048Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingAbbVieAug 2027165
NCT03785184Multiple Myeloma · United States, Australia, Canada and more2WithdrawnAbbVieAug 22, 20190
NCT03584009Breast Neoplasms · United States, Australia, Canada and more2TerminatedHoffmann-La RocheAug 5, 2020103
NCT03567616Multiple Myeloma · United States, Spain, United Kingdom2TerminatedAbbVieJun 18, 20208
NCT03557619Hematologic Neoplasms · United States, Australia1RecruitingAbbVieMar 21, 202612
NCT03539744Multiple Myeloma · United States, Australia, Canada and more3Active, not recruitingAbbVieAug 2026265
NCT03484520Neoplasms · United States, Australia, Spain1TerminatedAbbVieDec 1, 202248
NCT03441555Leukemia, Myeloid, Acute · United States, Germany, United Kingdom1CompletedAbbVieJan 25, 202136
NCT03406156Leukemia, Lymphocytic, Chronic, B-Cell · United States3CompletedAbbVieOct 12, 2021120
NCT03312530Multiple Myeloma · Czechia, Denmark, France and more2CompletedHoffmann-La RocheMay 18, 202149
NCT03314181Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingAbbVieMay 2031156
NCT03236857Neoplasms · United States, Australia, Canada and more1CompletedAbbVieApr 19, 2023143
NCT03181126Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia1CompletedAbbVieNov 11, 202069
NCT03112174Lymphoma, Mantle-Cell · United States, Australia, Belgium and more3CompletedAbbVieJun 26, 2024366
NCT03069352Leukemia, Myeloid, Acute · United States, Argentina, Australia and more3CompletedAbbVieFeb 15, 2019211
NCT02993523Leukemia, Myeloid, Acute · United States, Australia, Austria and more3Active, not recruitingAbbVieDec 1, 2021443
NCT02980731Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Bulgaria and more3CompletedAbbVieDec 29, 2021210
NCT02966782Myelodysplastic Syndromes · United States, Australia, Germany1CompletedAbbVieApr 5, 202370
NCT02966756Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, New Zealand and more2Active, not recruitingAbbVieDec 203066
NCT02942290Myelodysplastic Syndromes · United States, Australia, Canada and more1CompletedAbbVieApr 15, 2026134
NCT02910583Leukemia · United States, Australia, Italy and more2CompletedAbbVieNov 12, 2020323
NCT02899052Multiple Myeloma · United States, Australia, Hungary and more2Active, not recruitingAbbVieJun 2027120
NCT02756611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more3CompletedAbbVieApr 10, 2019258
NCT02755597Multiple Myeloma · United States, Australia, Brazil and more3CompletedAbbVieMar 15, 2021291
NCT02287233Leukemia, Myeloid, Acute · United States, Australia, Germany and more2CompletedAbbVieAug 10, 202194
NCT02265731Lymphoma, Non-Hodgkin · Japan2CompletedAbbVieMar 12, 202138
NCT02242942Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedHoffmann-La RocheAug 17, 2018445
NCT02187861Lymphoma, Follicular · United States, Australia, Belgium and more2CompletedHoffmann-La RocheSep 27, 2016163
NCT02141282Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedAbbVieDec 22, 2021127
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedHoffmann-La RocheJun 28, 2017267
NCT02095574Lymphoma, Non-Hodgkin1WithdrawnAbbVieSep 20140
NCT02005471Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedHoffmann-La RocheMay 8, 2017389
NCT01994837Leukemia, Myeloid, Acute2CompletedAbbVieDec 201432
NCT01969695Lymphoma, Non-Hodgkin · United States1CompletedAbbVieDec 16, 201911
NCT01969682Lymphoma, Non-Hodgkin · United States1WithdrawnAbbVieMay 20140
NCT01969669Lymphoma, Non-Hodgkin · United States1CompletedAbbVieSep 201412
NCT01889186Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more2CompletedAbbVieOct 28, 2020158
NCT01794520Multiple Myeloma · United States, Belgium, France and more2CompletedAbbVieNov 29, 2021117

How it is read

Names in the registry

  • “Venetoclax”, 66 entries
  • “ABT-199”, 9 entries
  • “venetoclax”, 6 entries
  • “ABT-199 (Main Cohort)”, 1 entry
  • “ABT-199 (Safety Expansion Cohort)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.